Immunotherapy drug development powered by deep biology insights

Guided by long-term scientific research & in-depth biology insights, OncoImmune develops novel immune-modulators targeting innate checkpoint mechanisms [...] that can separate its therapeutic effect from toxicity. The company is looking for partners to drive clinical development & commercialization

Like Comment
Page of
Go to the profile of Oncoimmune


Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease. Founded in 2000 on the scientific discoveries of our founders, we have moved our lead product, CD24Fc, from a basic concept into clinical trials. CD24Fc has a novel mechanism of action that is applicable to a number of autoimmune diseases that has shown good safety and tolerability in a Phase I clinical trial in healthy volunteers. OncoImmune has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease (GvHD) for leukemia patients undergoing hematopoietic stem cell transplantation and in poised to launch a pivotal trial for the indication. OncoImmune also have a rich pipeline of immunotherapy products that are moving through preclinical testing.

No comments yet.